BioSpace News Archive

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the H.C. Wainwright & Co. 25th Annual Global Investment Conference, taking place September 11-13, 2023.

Theralase Technologies Inc. is pleased to announce that it has closed a non-brokered private placement offering (“Offering”) of units (“Units”).

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announce a multi-target collaboration to develop intravitreally-delivered adeno-associated viruses (AAVs) for ocular diseases, with options to add additional targets and tissue types.

Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, announced its unaudited financial results for the six months ended June 30, 2023.

Pleco Therapeutics BV, a specialty pharmaceutical company developing novel Plecoid™ therapies designed to detoxify the cancer microenvironment today announces the appointment of Dr Henno Welgemoed

Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, today published the latest specialist clinical trial report –“Gallbladder Cancer: Global Clinical Trials Landscape Report”.

Avidity Biosciences, Inc. announced that it is joining with patient communities to raise awareness during National Muscular Dystrophy Awareness Month, an annual observance that takes place every September to support families across the U.S. who are impacted by neuromuscular diseases.

Synaptogenix, Inc. (Nasdaq: SNPX) (“Synaptogenix” or the “Company”), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced findings from an independent study demonstrating the potential for Bryostatin-1 as a treatment strategy for amyotrophic lateral sclerosis (“ALS”), also known as Lou Gehrig’s Disease.

Procyrion, Inc. announced it has successfully secured new inpatient hospital ICD-10-PCS procedure codes applicable to its Aortix™ percutaneous mechanical circulatory support technology.

Strata Oncology, Inc. today announced new data showing its proprietary biomarker algorithm, Immunotherapy Response Score (IRS), supports informed clinical decisions for first-line treatment of patients with non-small cell lung cancer (NSCLC) beyond the standard of care biomarker PD-L1 immunohistochemistry (IHC).